WearOptimo’s life saving MicrowearableTM sensor technology is heading into production with a $30 million deal, which includes funding an advanced technology facility in Brisbane, Queensland.In March 2021, WearOptimo signed a $30 million project to set up an advanced manufacturing facility in Queensland. The funding is from the Queensland Government through the Essential Goods and Supply Chain Program (EGSCP), WearOptimo and the Australian National University (ANU) to build a globally competitive high-tech manufacturing facility to produce up to 26 million MicrowearableTM sensors each year. This project is also supported by the Australian National Fabrication Facility
(ANFF) and other partners. The facility will be one-of-a-kind in Australia and will be key in creating hundreds of high-value jobs throughout this decade.
Founded in 2018, WearOptimo is based in Brisbane and became the Australian National University’s first innovation company. In 2020, WearOptimo signed a deal with Aspen Medical to be an exclusive distributor/reseller of the hydration MicrowearableTM sensors within Australia and globally. The commercial partnership will target the mining, resource, and energy sectors where hydration monitoring of workers is of paramount importance.
Other WearOptimo milestones include:
- Awarded two grants from the AustralianGovernment (>$1.8 million) under the MTP Connect Biomedical Technology Horizons Grants program;
- First MicrowearableTM sensor patents filed;
- Prototype integrated commercialMicrowearableTM sensor; and
- Established a world-leading interdisciplinary team from the world’s leading universities, including the Australian National University, University of Oxford, University of Cambridge and Stanford University.The MicrowearableTMBy directly detecting biomarkers and body parameters in the skin, WearOptimo’s MicrowearablesTM instantly enable diagnosis and monitoring of a range of disorders in a simple, wearable format with immediate information available to patients, carers and clinicians.
The MicrowearableTM devices offer a unique platform for the interrogation of the human body. They are minimally invasive, pain-free and monitor clinically relevant data; and cloud-based services and analytics provide real-time feedback to the patient and clinicians for rapid decision making. Aggregated data analytics provide new insights to human health.
